Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.59% | 3.24% | -21.29% | -18.45% | -5.21% |
| Total Depreciation and Amortization | 5.62% | 4.66% | -0.97% | -5.61% | 0.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.01% | -1.63% | 3.06% | 3.78% | 6.41% |
| Change in Net Operating Assets | 95.08% | -49.06% | -12.95% | 132.46% | 149.64% |
| Cash from Operations | 12.47% | -2.58% | -31.49% | -10.51% | 19.07% |
| Capital Expenditure | -93.96% | -27.95% | -191.14% | 39.56% | -174.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -442.12% | 30.07% | -7.47% | 21.17% | 17.04% |
| Cash from Investing | -454.31% | 30.12% | -8.91% | 22.06% | 16.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 99,183.49% | -75.76% | 74.29% | 1,128.57% | -68.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 99,183.49% | -75.76% | 74.29% | 1,128.57% | -68.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.97% | 195.70% | -155.15% | 119.92% | 152.66% |